Sector Expert: Brian Marckx

Zacks Small-Cap Research

Image: Brian Marckx

Brian Marckx is the senior medical device/diagnostics analyst with Zacks Small-Cap Research, He covers small- and micro-cap medical device and diagnostic companies with a focus on development-stage companies with novel and emerging technologies, as well as already established names still flying under the radar. Prior to joining Zacks, Marckx worked as a high-yield bond analyst on Wachovia Securities' institutional trading desks, where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Marckx has been quoted in The Wall Street Journal, Barron's, Bloomberg Businessweek and Kiplinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. He graduated with a bachelor's degree in finance from St. John Fisher College, and received his master's degree in business administration from Wake Forest University. Marckx is also a Chartered Financial Analyst.



Recent Quotes

"DRRX's licensing agreement with Gilead validates the SABER technology."

— Brian Marckx, Zacks Small-Cap Research (8/19/19)
more >

"The market for DRRX's POSIMIR could be substantial."

— Brian Marckx, Zacks Small-Cap Research (6/27/19)
more >

"Early data from DRRX's Phase 2a trial in AH are highly compelling."

— Brian Marckx, Zacks Small-Cap Research (5/16/19)
more >

"DUR-928 is where we believe most of the upside values lies in DRRX."

— Brian Marckx, Zacks Small-Cap Research (3/13/19)
more >

"Initial dosing in DRRX's Phase 1b NASH study is now slated for Q1/19."

— Brian Marckx, Zacks Small-Cap Research (1/11/19)
more >

"DRRX's Q3/18 revenue benefited from a $5M milestone from Indivior."

— Brian Marckx, Zacks Small-Cap Research (11/16/18)
more >

"VIVE's Q1/18 total revenue was $3.7M, up 22% year over year."

— Brian Marckx, Zacks Small-Cap Research (5/17/18)
more >

"VIVE has now grown revenue sequentially for 13 consecutive quarters."

— Brian Marckx, Zacks Small-Cap Research (3/28/18)
more >



Due to permission requirements, not all quotes are shown.